Shell Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Shell Asset Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-5,901	Closed	-$366K	–	1475
2020 Q4	$366K	Hold	5,901	–	–	0.01%	926
2020 Q3	$351K	Hold	5,901	–	–	0.01%	843
2020 Q2	$412K	Buy	5,901 +747	+14%	+$47.4K	0.01%	748
2020 Q1	$234K	Sell	5,154 -80	-2%	-$4.53K	0.01%	962
2019 Q4	$341K	Sell	5,234 -197	-4%	-$13.2K	0.01%	1015
2019 Q3	$337K	Sell	5,431 -46	-0.8%	-$2.89K	0.01%	1039
2019 Q2	$390K	Sell	5,477 -125	-2%	-$9.21K	0.01%	1004
2019 Q1	$439K	Hold	5,602	–	–	0.01%	965
2018 Q4	$474K	Sell	5,602 -481	-8%	-$51.3K	0.01%	860
2018 Q3	$1.04M	Buy	+6,083	New	+$917K	0.02%	639
2016 Q4	–	Sell	-7,906	Closed	-$503K	–	1082
2016 Q3	$503K	Buy	+7,906	New	+$581K	0.01%	864

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Shell Asset Management's LGND Position: Q1 2021 in Review

Shell Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q1 2021, closing a stake of 5,901 shares — an estimated $366K sold.

Shell Asset Management first reported a position in LGND in Q3 2016 and held it in 11 quarters. The position peaked at $1.04M in Q3 2018. 228 funds tracked by Wall St. Rank hold LGND as of Q1 2021.

Shell Asset Management reported no remaining Ligand Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Shell Asset Management sold 5,901 Ligand Pharmaceuticals shares in Q1 2021, an estimated $366K.
Shell Asset Management first reported a position in Ligand Pharmaceuticals in Q3 2016 and held it in 11 quarters.
Shell Asset Management's Ligand Pharmaceuticals position peaked at $1.04M in Q3 2018.
228 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2021.

Based on Shell Asset Management's 13F filing for Q1 2021, filed 10 May 2021.